Nektar Therapeutics Financial Ratios
NASDAQ: NKTRHealthcareBiotechnologyUSD
41.17+0.37 (+0.91%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Nektar Therapeutics ratio analysis
Nektar Therapeutics earned a net margin of -297.1% in FY 2025, down from -120.9% a year earlier. Gross margin was 100.0% compared with a median of 81.4% over the prior 9 years. Return on equity reached -182.6%, meaning Nektar Therapeutics generated -1.83 dollars of profit for every dollar of shareholders' equity.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Nektar Therapeutics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | — | — | — | — | — | — | — | 134.76 | — | — |
| Price / sales | 13.26 | 2.30 | 17.71 | 68.92 | 364.50 | 297.80 | 470.17 | 72.40 | 454.01 | 155.30 |
| Price / book | 8.15 | 3.72 | 12.18 | 17.30 | 54.67 | 42.27 | 38.34 | 50.30 | 1,590.64 | 291.55 |
| Gross margin | 100.0% | 68.8% | 62.5% | 76.5% | 75.6% | 87.3% | 81.4% | 98.0% | 90.1% | 81.7% |
| Operating margin | -253.7% | -106.9% | -292.6% | -408.6% | -437.8% | -278.0% | -383.9% | 57.6% | -19.4% | -68.2% |
| Net margin | -297.1% | -120.9% | -306.3% | -400.0% | -514.0% | -290.6% | -384.5% | 57.1% | -31.4% | -92.8% |
| Free cash flow margin | -377.8% | -180.0% | -214.7% | -336.4% | -419.6% | -209.6% | -309.7% | 59.0% | -29.3% | -74.6% |
| Return on equity (ROE) | -182.6% | -195.9% | -210.8% | -100.4% | -77.1% | -41.3% | -31.4% | 39.7% | -110.1% | -174.2% |
| Return on assets (ROA) | -58.5% | -39.2% | -69.4% | -51.8% | -46.9% | -28.9% | -22.3% | 31.7% | -19.0% | -27.0% |
| Debt / equity | — | — | — | — | — | — | 0.00 | 0.14 | 2.79 | 2.76 |
| Current ratio | 4.97 | 4.26 | 6.45 | 8.00 | 9.34 | 9.83 | 4.02 | 17.53 | 5.82 | 5.90 |
| Revenue growth | -43.9% | 9.2% | -2.1% | -9.7% | -33.4% | 33.4% | -90.4% | 287.8% | 86.0% | -28.3% |
| EPS growth | — | — | — | — | — | — | -166.7% | — | — | — |